H-LLIIVILGV-OH

Ref. 3D-PP46266

Información del producto

• Nombre: H-LLIIVILGV-OH
• Sinónimos: NH2-Leu-Leu-Ile-Ile-Val-Ile-Leu-Gly-Val-OH

Descripción

Peptide H-LLIIVILGV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-LLIIVILGV-OH include the following: Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion M Munder, M Engelhardt, D Knies, S Medenhoff - PloS one, 2013 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0063521 Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by M Munder, M Engelhardt, D Knies, S Medenhoff - 2013 - academia.eduhttps://www.academia.edu/download/67348924/Cytotoxicity_of_Tumor_Antigen_Specific_H20210517-875-evshmr.pdf Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro I Kramer, M Engelhardt, S Fichtner, B Neuber - , 2016 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1139662 Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma I Herth, M Witzens-Harig, P Beckhove , D Hose - Experimental , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0301472X12005358 Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma B Neuber, I Herth, C Tolliver, S Schoenland - The Journal of , 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/187/2/1047/38767

• Marca: Biosynth